Stunting
Conditions
Brief summary
The purpose of this study is to investigate the effects of double fortification (iron and zinc) in synbiotic milk (L.plantarum Dad13 and fructooligosaccharides) on under 5 years stunted children growth, gut microbiota composition, blood zinc and hemoglobin level, and cognitive level.
Detailed description
This is a parallel, quadruple-blind, randomized controlled trial to determine the effects of double fortification (iron and zinc) in synbiotic milk (containing 7 billion CFU L.plantarum Dad13 and 4 g fructooligosaccharides) on the gut microbiota composition, body height and weight, blood zinc and hemoglobin level, and cognitive level in under 5 years stunted children subjects. The duration of the study is 4 months, including a 2-week pre test and informed consent before randomization of subjects into treatment or control group, a 12-week intervention period, and a 2-week post test after the end of intervention. During the intervention period, subjects will be instructed to take 100 ml of fortified synbiotic milk or non-fortified synbiotic milk per day. They will also be asked to document consumed milk, any unusual symptoms or side effects of treatment. Diet will be monitored via 24-h dietary recalls and SQ-FFQ before and after treatment respectively. Changes in the gut microbiota composition will be determined by measuring bacterial population levels (Bifidobacteria, Lactobacillus, Enterobacteria, Prevotella, and Bacteroides) in stool sampled collected at baseline and 12 weeks by qPCR. Metabolic markers (calprotectin, hemoglobin, and zinc level) will be measured at baseline and 12-weeks in serum and plasma using biochemical and immuno-assay. Changes in the cognitive level, height for age Z-score collected at baseline and 12 weeks using Bayley Scales of Infant Development, 2nd Edition .
Interventions
DIETARY_SUPPLEMENTfortified synbiotic milk
100 ml fortified (7,47 mg ferrous sulphate and 4,33 mg zinc acetate) synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
DIETARY_SUPPLEMENTnon-fortified synbiotic milk
100 ml non-fortified synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
Sponsors
Gadjah Mada University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Intervention group given fortified synbiotic milk, control group given non-fortified synbiotic milk
Eligibility
Sex/Gender
ALL
Age
2 Years to 5 Years
Healthy volunteers
Yes
Inclusion criteria
* age between 2 year to 5 years * height per age z-score under -2 (stunting) * parents sign inform consent form
Exclusion criteria
* have congenital abnormality * lactose intolerant * use antibiotic for more than 2 weeks * consume micronutrient supplement (especially iron and zinc) in the last 3 months * diagnose with chronic diseases and infection that interfere metabolism (i.e. tuberculosis, HIV, autoimmune disease, diabetes mellitus type 1) * suffer marasmus and/or kwashiorkor * not willing to continue the intervention
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Gut Microbiota Associated to Synbiotic Milk Treatment | 3 months | Stools samples will be collected and analyzed before and after the intervention and compared between groups (Lactobacillus, Bifidobacteria, Bacteroides, Prevotella, and Enterobacteria) using qPCR method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Height per Age Z-score Associated to Synbiotic Milk Treatment | 3 months | Height data will be collected and analyzed before and after the intervention and compared between groups |
| Changes in Hemoglobin Level Associated to Synbiotic Milk Treatment | 3 months | Hemoglobin data will be collected and analyzed before and after the intervention and compared between groups using biochemistry method |
| Changes in Calprotectin Level Associated to Synbiotic Milk Treatment | 3 months | Calprotectin data will be collected and analyzed before and after the intervention and compared between groups using immuno-assay method |
| Changes in Blood Zinc Level Associated to Synbiotic Milk Treatment | 3 months | Calprotectin data will be collected and analyzed before and after the intervention and compared between groups using Atomic Absorbance Spectrophotometry method |
| Changes in Cognitive Level Associated to Synbiotic Milk Treatment | 3 months | Cognitive level will be collected and analyzed before and after the intervention and compared between groups using Bayley Scales of Infant Development, 2nd Edition (BSID). This part of BSID evaluation, which yields a score called the mental development index, evaluates several types of abilities: sensory/perceptual acuities, discriminations, and response; acquisition of object constancy; memory learning and problem solving; vocalization and beginning of verbal communication; basis of abstract thinking; habituation; mental mapping; complex language; and mathematical concept formation. Total score from test will determine mental development index of children : accelerated performance (score ≥85), within normal limit (score 70-84), mildly delayed performance (score 55-69), and significantly delayed performance (score \<55). |
| Changes in Psychomotor Level Associated to Synbiotic Milk Treatment | 3 months | Psychomotor data will be collected and analyzed before and after the intervention and compared between groups using Bayley Scales of Infant Development, 2nd Edition (BSID). This part of the BSID assesses the degree of body control, large muscle coordination, finer manipulatory skills of the hands and fingers, dynamic movement, postural imitation, and the ability to recognize objects by sense of touch (stereognosis). Total score from test will determine motor development index of children : accelerated performance (score ≥85), within normal limit (score 70-84), mildly delayed performance (score 55-69), and significantly delayed performance (score \<55). |
Countries
Indonesia
Contacts
Primary ContactSiti Helmyati, DR.
Backup ContactLily A. Lestari, DR.
Outcome results
None listed